Covid19-Sources

Scientific Reports - Insights on the neurocognitive mechanisms underlying hippocampus-dependent memory impairment in COVID-19

Pérez et al. evaluate whether antibody levels and neutralization titers correlate with protection against SARS-CoV-2, including Omicron sub-variants BQ.1 and XBB, in a cohort of Spanish healthcare workers. They find an association that wanes over time, highlighting the need for updated vaccination strategies.

They told you COVID-19 vaccines would kill millions. The data told a different story.

Repeatedly mass infecting kids with COVID is not a public health strategy. It's a fast pass to declining population health

Unsere Kolumnistin Margarete Stokowski hat Long Covid. Und muss sich gegenüber vielen Leuten erklären.

Radical prostatectomy (RP) has been used as the main primary treatment for prostate cancer (PCa) for many years with excellent oncologic results. However, approximately 20-40% of those patients has failed to RP and presented biochemical recurrence ...

Researchers at UCLA Health analyzed medical records of more than 3,000 patients who had been hospitalized for Covid between 2020 and 2022.

Pediatric Research - Cord blood cytokines/chemokines linked to delays in toddlers exposed to SARS-CoV-2 prenatally

DMZ – POLITIK / WISSEN / GESUNDHEIT ¦ AA ¦ Der Beitrag im "Pandemic Accountability Index" (Pandemie-Verantwortlichkeitsindex) vom letzten November, in dem über hundert Studien und Artikel zu den Auswirkungen des SARS-CoV-2-Virus auf den Körper berichtet wurde, ist mittlerweile über sechs Monate alt. Seitdem wurden weitere Forschungsergebnisse veröffentlicht. Es ist daher an der Zeit, unser Verständnis dafür zu aktualisieren, warum es so wichtig ist, Infektionen mit diesem gefährlichen und behindernden Virus zu verhindern. Laut der Weltgesundheitsorganisation (WHO) leiden allein in Europa über 36 Millionen Menschen an Langzeitfolgen von COVID, einem Oberbegriff für zahlreiche medizinische Komplikationen. Diejenigen, die behauptet haben, dass SARS-CoV-2 relativ harmlos oder "mild" sei und COVID-19 "nur eine Erkältung/Grippe" sei, müssen sich mit der ständig wachsenden Anzahl wissenschaftlicher Forschungsergebnisse auseinandersetzen, die seitdem veröffentlicht wurden. Kinder und COVID: COVID-19 ist eine der häufigsten Todesursachen bei Kindern und Jugendlichen in den USA (University of Oxford). Anstieg von Diabetes bei Kindern und Jugendlichen (Jama Network). Auch milde Infektionen können zu langfristigen Folgen führen, einschließlich Long-COVID (University of Minnesota). Mehr als 70% der Haushaltsübertragungen von COVID in den USA gehen von Kindern aus (CIDRAP). Kinder können nach einer asymptomatischen oder milden COVID-19-Erkrankung langfristige Herzmuskeldeformationen entwickeln (MDPI Open Access Journals). Langzeitfolgen bei Jugendlichen und jungen Erwachsenen nach mildem COVID-19 (Frontiers in Immunology). Einige Kinder zeigen nach einer COVID-19-Infektion Symptome wie Fieber, Erbrechen und Augenschmerzen (NHK). COVID-19 kann bei Kindern autoimmune Reaktionen auslösen (HCPLive). Erhöhte Raten von Asthma, Myokarditis, Diabetes und anderen Erkrankungen bei Kindern mit bestätigtem COVID-19 (Medical Journal of Australia). Über 30% der Kinder zeigen auch nach 2 Monaten noch Symptome, und 2,3% haben nach 6 Monaten immer noch anhaltende Symptome (Frontiers in Pediatrics). Das Immunsystem von Kindern entwickelt keine "adaptiven" Erinnerungen, die vor einer erneuten SARS-CoV-2-Infektion schützen (Garvan Institute of Medical Research). Die Prävalenz von Langzeitfolgen bei COVID-19 liegt bei 23,36% (ScienceDirect). Die Omikron-Variante verursacht siebenmal mehr Todesfälle bei hospitalisierten Kindern als die Influenza (South China Morning Post). In Ohio haben zwischen 30.000 und 70.000 Kinder Long COVID (US News). COVID-19 kann zu Herzerkrankungen bei Kindern führen (MDPI Open Access Journals). Entzündliche Erkrankungen bei Kindern nach COVID-19 (ScienceDirect). Neurologische Komplikationen nach COVID-19 bei Kindern (American Academy of Pediatrics). Augenmanifestationen von COVID-19 bei Kindern (SageJournals). Beeinträchtigungen der Gesundheit bei Kindern und Jugendlichen nach einer COVID-19-Erkrankung (American Academy of Pediatrics). Nahezu alle mit COVID-19 infizierten Kinder zeigen Anzeichen von Schädigung der Blutgefäße (Blood Advances). Eine Studie zeigt, dass vorherige COVID-19-Infektionen mit einem signifikant erhöhten Risiko für RSV-Infektionen bei Kindern in Verbindung gebracht werden (medRxiv). Zwischen 12 und 16% der Kinder und Jugendlichen, die mit Omikron infiziert waren, erfüllen die Definition von Long COVID (Journal of Pediatrics). Diabetes-Typ-1-Inzidenz und -Risiko bei Kindern mit einer COVID-19-Diagnose (Jama Network). Prävalenz von Long COVID bei Kindern und Jugendlichen beträgt 25,24%, am häufigsten mit Stimmungssymptomen (Nature). Ungewöhnlicher Anstieg von Hirnabszessen bei amerikanischen Kindern (CDC). Veränderte Verformung der roten Blutkörperchen bei Kindern und Jugendlichen nach SARS-CoV-2-Infektion (Nature). Kinder haben ein ähnliches Risiko für Langzeitfolgen von Long COVID bei einer erneuten Infektion wie bei der Erstinfektion (Journal of Pediatrics). SARS-CoV-2 kann sich über Wochen bis Monate systemisch ausbreiten und persistieren, unabhängig von der Schwere der Erkrankung (Lancet). Originallinks: COVID-19 is a leading cause of death in children and young people in the US (University of Oxford) Surge in child and teen diabetes (Jama Network) “Two US studies describe pediatric COVID...7.0% of hospitalized children developed neurologic complications such as seizures...even mild infections can lead to long COVID.” (University of Minnesota) More than 70% of US household COVID spread started with a child (CIDRAP) "Persistence of LV myocardial deformation abnormalities in previously healthy children with an asymptomatic or mildly symptomatic COVID-19 course after an average follow-up of 148 ± 68 days.” (MDPI Open Access Journals) “Inflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19” (Frontiers in Immunology) “Fever, vomiting, and eye pain are a few of the symptoms afflicting a small number of children after they have been infected with COVID-19.” (NHK) COVID-19 May Trigger Autoimmune Responses in Children (HCPLive) “…increased rates of asthma, myocarditis and cardiomyopathy, cardiac dysrhythmias, diabetes, renal failure, venous thromboembolism, and coagulation disorders in children with laboratory‐confirmed COVID‐19 compared with children without COVID‐19.” (Medical Journal of Australia) “32.6% of the children had persistent symptoms at 2 months, 9.3% at 4 months, and 2.3% at 6 months” (Frontiers in Pediatrics) Children’s immune systems do not develop ‘adaptive’ memory to protect against second time SARS-CoV-2 infection (Garvan Institute of Medical Research) Based on 40 studies with 12,424 individuals, the pooled prevalence of any long COVID was 23.36 % (ScienceDirect) “Omicron strain causes 7 times more deaths among hospitalised children than influenza” (South China Morning Post) “In Ohio, between 30,000 and 70,000 children have long COVID.” (US News) COVID-19 Heart Lesions in Children: Clinical, Diagnostic and Immunological Changes (MDPI Open Access Journals) Multisystem inflammatory syndrome in children: A dysregulated autoimmune disorder following COVID-19 (ScienceDirect) COVID-19 and Acute Neurologic Complications in Children (American Academy of Pediatrics) Ocular manifestations of COVID-19 in pediatric patients (SageJournals) Health Impairments in Children and Adolescents After Hospitalization for Acute COVID-19 or MIS-C (American Academy of Pediatrics) "Virtually all children infected with COVID-19 show signs of blood vessel damage" (Blood Advances) "Findings from our study support that prior COVID-19 infection was associated with a significantly increased risk for RSV infection and was a driving force for the 2022 surge of severe pediatric RSV cases in the US." (medRxiv) “12-16% children and youth infected with Omicron met the research definition of #LongCovid at 3 and 6 months after infection, with no evidence of difference between cases of first-positive and reinfection” (Journal of Pediatrics) Type 1 Diabetes Incidence and Risk in Children With a Diagnosis of COVID-19 (Jama Network) Long-COVID in children and adolescents: prevalence of long-COVID was 25.24%, most prevalent clinical: mood symptoms (16.50%) - (Nature) Abnormal Surge of Brain Abscesses in American Children, CDC Says (ScienceAlert) Increased red blood cell deformation in children and adolescents after SARS-CoV-2 infection (Nature) Children are at as much risk of Long COVID disability from reinfection as they are from primary infection (Journal of Pediatrics) “in children, independent from disease severity, SARS-CoV-2 can spread systemically and persist for weeks to months.” (Lancet) NEUROLOGISCHE BEEINTRÄCHTIGUNGEN: Geruchs- und Geschmacksstörungen nach COVID-19 (BMJ). Neuropsychologische Defizite bei Patienten mit anhaltenden COVID-19-Symptomen (Nature). Neuroinflammation nach COVID-19 mit anhaltenden depressiven und kognitiven Symptomen (JAMA Psychiatry). SARS-CoV-2 fördert die Beseitigung synaptischer Verbindungen durch Mikrogliazellen im menschlichen Gehirn (Nature). Langfristige Auswirkungen von COVID-19 auf kognitive Funktionen bis zu 6 Monate nach der Entlassung: Rolle von Depressionen und Auswirkungen auf die Lebensqualität (Springer Link). SARS-CoV-2 ist mit Veränderungen der Gehirnstruktur verbunden (Nature). Jeder vierte Patient zeigt kognitive Defizite nach einem milden COVID-19-Verlauf (NIH). Neurokognitive und psychiatrische Symptome nach COVID-19-Infektion: Nachweise aus Labor- und Bevölkerungsstudien (ScienceDirect). COVID-19 und kognitive Beeinträchtigungen: Neuroinvasive und Blut-Hirn-Schrankenstörungen (Journal of Neuroinflammation). COVID-19 kann dazu führen, dass Gehirnzellen abnormal fusionieren und Beeinträchtigungen der Gehirnfunktion verursachen, bei 10% der untersuchten Fälle kommt die neuronale Aktivität vollständig zum Stillstand (ScienceAdvances). COVID-19 kann auch durch Hyperaktivierung der Immunantwort, Zelltod oder Entzündungen verschiedene Hirnregionen beeinträchtigen und zu Gedächtnisstörungen führen (CIDRAP). Rasche Verschlechterung der Demenz nach COVID-19 (NIH). Originallinks: Smell and taste dysfunction after covid-19 (BMJ) Neuropsychological deficits in patients with persistent COVID-19 symptoms (Nature) Neuroinflammation After COVID-19 With Persistent Depressive and Cognitive Symptoms (JAMA Psychiatry) SARS-CoV-2 promotes microglial synapse elimination in human brain organoids (Nature) Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: role of depression and impact on quality of life (Springer Link) SARS-CoV-2 is associated with changes in brain structure (Nature) 1 in 4 Showing Cognitive Deficits After Mild Case (NIH) Neurocognitive and psychiatric symptoms following infection with COVID-19: Evidence from laboratory and population studies (ScienceDirect) COVID-19 and cognitive impairment: neuroinvasive and blood‒brain barrier dysfunction (Journal of Neuroinflammation) Covid cause...

Increases in infections due to SARS-CoV-2, associated with an increase in detections of the NB.1.8.1 variant, have been observed in some countries in Asia (including China, Hong Kong, Singapore) in recent weeks. ECDC and WHO have classified NB.1.8.1 as a variant under monitoring (VUM).

DMZ – GESUNDHEIT ¦ Anton Aeberhard ¦ WHO stuft NB.1.8.1 als „Variante unter Beobachtung“ ein – Immunität lässt nach – Experten rufen zu Auffrischungsimpfungen auf Die Weltgesundheitsorganisation (WHO) und internationale Virologen warnen vor einer neuen Variante des Coronavirus: NB.1.8.1, in Großbritannien auch „Nimbus“ genannt. Die Untervariante gehört zur weitverbreiteten Omikron-Familie und zeigt laut ersten Analysen eine deutlich erhöhte Übertragbarkeit. In mehreren Ländern, darunter auch Deutschland, wurden bereits Infektionen mit Nimbus nachgewiesen. Wie die britische Gesundheitsbehörde UKHSA berichtet, sind die Positivraten für Covid-19 in diesem Frühjahr auf den höchsten Stand des Jahres gestiegen – 97 Prozent über dem Niveau vom März. Auch in China, Singapur und Hongkong sorgte Nimbus für einen sprunghaften Anstieg der Infektionen. Die WHO hat NB.1.8.1 daher Mitte Mai als „Variante unter Beobachtung“ eingestuft. In Deutschland wurde die Variante laut Robert Koch-Institut (RKI) erstmals im März 2025 entdeckt. Bereits im Mai waren 16,7 Prozent aller Corona-Fälle auf Nimbus zurückzuführen. Zwar liegt die allgemeine Infektionsrate derzeit noch auf niedrigem Niveau, doch Experten warnen vor einem möglichen Wiederanstieg im Sommer – auch durch das wärmere Wetter, das geselliges Verhalten und damit Infektionsrisiken begünstigt. „Es ist sehr wahrscheinlich, dass wir in den kommenden Wochen einen Anstieg der Infektionen erleben werden“, erklärt Professor Lawrence Young, Virologe an der Universität Warwick, gegenüber dem britischen i Paper. Das genaue Ausmaß lasse sich jedoch nur schwer prognostizieren. Symptome wie bei Omikron – aber höhere Ansteckung Die Symptome unterscheiden sich laut WHO und britischem Gesundheitsdienst nicht wesentlich von früheren Omikron-Varianten. Zu den häufigsten Beschwerden gehören Halsschmerzen, Fieber, Muskelschmerzen, Müdigkeit und gelegentlich Husten. Einige Betroffene berichten von besonders starken Rachenschmerzen, die als „rasiermesserscharf“ beschrieben werden. Nach Einschätzung von Virologen könne Nimbus menschliche Zellen effizienter infizieren als frühere Varianten und besitze eine gewisse Fähigkeit zur Immunflucht – also zur Umgehung bereits bestehender Immunabwehr durch frühere Infektionen oder Impfungen. Dies könnte erklären, warum es trotz vorhandener Grundimmunität zu vermehrten Infektionen kommt. Gleichzeitig gibt es bislang keine Hinweise, dass die Variante häufiger zu schweren Verläufen oder Todesfällen führt. Die WHO stuft das öffentliche Gesundheitsrisiko daher weiterhin als „niedrig“ ein. In Großbritannien waren im Mai rund 300 Todesfälle mit Covid-19 registriert – ein im Vergleich zu früheren Wellen niedriger Wert. WHO und Experten rufen zu Auffrischungsimpfungen auf Gerade für ältere oder vorerkrankte Menschen könnte Nimbus dennoch ein ernstes Risiko darstellen. Britische Experten betonen, dass die Immunität vieler Menschen inzwischen nachgelassen habe – sei es durch Zeitablauf seit der letzten Impfung oder durch schwächere Immunantworten bei bestimmten Bevölkerungsgruppen. Daher empfehlen Virologen weiterhin Auffrischungsimpfungen. Die aktuell verfügbaren Impfstoffe, die an Omikron angepasst wurden, dürften nach Einschätzung von Fachleuten auch gegen Nimbus Schutz bieten – insbesondere gegen schwere Verläufe und Krankenhausaufenthalte. „Wir müssen die Impfraten bei Risikogruppen aufrechterhalten, um unnötige Todesfälle zu verhindern“, heißt es in einer aktuellen Einschätzung der WHO. Infektionsschutz bleibt auch im Sommer wichtig Auch wenn keine neuen gesetzlichen Maßnahmen geplant sind, erinnern Fachleute daran, dass klassische Schutzmaßnahmen wie das Tragen von FFP2-Masken in Innenräumen, ausreichende Belüftung und freiwillige Tests bei Symptomen nach wie vor hilfreich sein können – gerade bei engem Kontakt mit gefährdeten Personen. Nimbus ist ein weiteres Beispiel dafür, dass das Coronavirus nicht verschwunden ist. Auch fünf Jahre nach Beginn der Pandemie bleibt Covid-19 eine ernstzunehmende Erkrankung – wenn auch mit veränderter Dynamik. Der Umgang mit neuen Varianten erfordert daher weiterhin Wachsamkeit, gezielte Prävention und eine wissenschaftsbasierte Kommunikation.

l-Theanine is a unique non-protein amino acid found abundantly in tea leaves. Interest in its potential use as a dietary supplement has surged recentl…

Using the guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), this meta-analysis (MA) tried to figure out how well creatine (Cr) improves metabolic performance. We searched Google Scholar, PubMed, and the ...

The symptoms of long COVID are well-documented. However, the long-term effects beyond 2 years remain poorly understood due to a lack of data. This systematic review and meta-analysis examined the pre...

Learn two supplements for Nonalcoholic Fatty Liver Disease, or NAFLD.

Background During the COVID-19 pandemic there were reports of an increased association between COVID 19 and various autoimmune diseases (AID) in adults. This study aims to investigate the incidence of AIDs in children before and during the pandemic and explores potential links to SARS-CoV-2 vaccination. Methods We analyzed 493,705 anonymized medical records from Maccabi Healthcare Services, Israel’s second-largest healthcare provider, to study AID incidence during 2014–2022. The study period was divided into three phases: two pre-pandemic phases of equal duration (A and B) and a pandemic phase (C). Results Of 4,596 (0.9%) patients diagnosed with an AID in the cohort, incidence rates were 0.9% for Group A (2014–2016), 1.0% for Group B (2017–2019), and 0.9% for Group C (2020–2022) (p = 0.13). Logistic regression showed no significant differences in overall autoimmune disease incidence between the pre-COVID and COVID periods. Notably, specific conditions like celiac disease showed reduced incidence in Group A (OR 0.8309, p = 0.0071) while arthritis was significantly more common in Groups A and B. Additionally, COVID-19 diagnosis was not significantly associated with increased autoimmune disease risk (HR 1.092, p = 0.491); however, receiving at least one COVID vaccine was linked to higher risk (HR 1.2323, p = 0.0033). Conclusion Our findings suggest that the overall incidence of new-onset autoimmune diseases in children remained relatively stable during the COVID-19 pandemic. The study indicates a potential association between COVID-19 vaccination and an increased risk of developing autoimmune diseases, necessitating further research to elucidate long-term effects in the pediatric population.

With the COVID-19 pandemic becoming endemic, vigilance for Long COVID-related cardiovascular issues remains essential, though their specific pathophys…

Importance Long COVID, a chronic condition following SARS-CoV-2 infection, affects millions of people worldwide and can lead to significant functional impairment. Estimates of long COVID risk after a first COVID-19 infection vary, and data on risk following reinfections remain lacking. Objective To estimate and compare long COVID risk and severity with first COVID-19 infection versus reinfections among healthcare workers (HCWs). Design Retrospective cohort study based on an electronic survey among Quebec HCWs conducted between May 16 and June 15, 2023. A short telephone survey among randomly selected non-respondents further assessed potential response bias. Setting Population-based study in Quebec, Canada. Participants 397 222 HCWs were invited to participate in the electronic survey and 10 500 in the telephone survey. Main outcomes and measures We defined long COVID cases as HCWs self-reporting COVID-19-attributed symptoms lasting ≥12 weeks, classified as mild, moderate, or severe based on perceived symptom intensity. We compared self-reported symptoms and functional limitations of cases to COVID controls (infected participants without long COVID) and non-COVID controls (uninfected participants). Risk and prevalence were estimated by number of infections, likely infecting variant and perceived acute COVID-19 severity. We conducted symptom clustering analyses using unsupervised learning techniques. Results Estimated long COVID risk following any COVID-19 infection was similar among 22 496 online survey participants (17.0% [95%CI, 16.3%–17.6%] and 3 978 telephone survey participants (15.9% [14.6%–17.2%]. The cumulative risk increased with the number of infections, but reinfections were associated with three times lower risk of long COVID than first infections. Pre-Omicron infections and severe acute COVID-19 episodes correlated with higher long COVID risk and severity. Among prevalent long COVID cases, 43% were moderate and 33% severe. Compared to controls, dyspnea, neurocognitive symptoms, post-exertional malaise and smell/taste disturbances were most strongly associated with long COVID. Cluster analysis identified seven symptom groups with systemic, neurocognitive, pulmonary, and mood-related clusters being the most prevalent. Severe long COVID cases exhibited multiple symptom clusters and greater functional limitations. Conclusions Long COVID is a common and disabling condition among HCWs. Societal and healthcare burden remains important and will continue to accrue given ongoing SARS-CoV-2 transmission and long COVID risk with reinfections. Question Does the risk and severity of long COVID differ for first COVID-19 infections versus reinfections among healthcare workers in Quebec, Canada? Findings The risk of long COVID was ∼15% with first COVID-19 infection, but three-fold lower with reinfections. Risk was higher with COVID-19 infections due to ancestral strains and with more severe acute episodes. Long COVID risk and severity compromised self-rated health, physical capacity and cognitive function. Meaning Long COVID is a common and disabling condition among workers. Societal and healthcare burden remains important and will continue to accrue given ongoing SARS-CoV-2 transmission and long COVID risk with reinfections. ### Competing Interest Statement SC, MO and IZD report funding from the Ministere de la sante et des services sociaux du Quebec to conduct this work, paid to their institution. SC reports funding from the Public Health Agency of Canada for unrelated work, paid to her institution. ELF reports grants from the Canadian Institutes of Health Research unrelated to this work and paid to his institution. Her site participated in an interventional trial conducted by Laurent Pharma. CAM is copresident of the Association Quebecoise de l encephalomyelite myalgique. DMS reports grants from the Public Health Agency of Canada, the Pacific Public Health Foundation, the Canadian Institutes of Health Research and the Michael Smith Foundation for Health Research for unrelated work, paid to her institution. GD reports having participated as medical advisor on the provincial Public Health scientific committee on COVID-19 for Quebec Ministry of Health and Social Services. AP reports grants from the Canadian Institutes of Health Research unrelated to this work and paid to his institution. Other authors have no conflict of interest to declare. ### Funding Statement This study was funded by Ministère de la Santé et des Services Sociaux du Québec and the Fonds de recherche du Québec. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Research Ethics Committee of CHU de Québec-Université Laval gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Underlying data cannot be shared publicly by authors, because it belongs to the Ministere de la sante et des services sociaux du Quebec and data access to researchers was given under the legal mandate of the Quebec National Director of Public Health. A request for data should be addressed to the research access centre designated by Quebec Government in accordance with the act respecting health and social services information ().

Muscle fatigue and cognitive disturbances persist in patients after recovery from acute COVID-19 disease. However, there are no specific treatments for post-COVID fatigue. Objective: To evaluate the efficacy and safety of the health supplements ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (probiotic complex) in patients suffering from COVID-19 induced fatigue. A randomized, multicentric, double blind, placebo-controlled trial was conducted in 200 patients with a complaint of post-COVID fatigue. The test arm (n = 100) received the oral supplements for 14 days and the control arm (n = 100) received a placebo. Treatment efficacy was compared using the Chalder Fatigue scale (CFQ-11), at various time points from days 1 to 14. The supplemental treatment resulted in resolution of fatigue in a greater percentage of subjects in the test vs. the control arm (91% vs. 15%) on day 14. Subjects in the test arm showed a significantly greater reduction in total as well as physical and mental fatigue scores at all time points vs. the control arm. The supplements were well tolerated with no adverse events reported. This study demonstrates that a 14 days supplementation of ImmunoSEB + ProbioSEB CSC3 resolves post-COVID-19 fatigue and can improve patients’ functional status and quality of life.

Updated vaccines will help maintain protection against disease as virus continues to evolve

The pandemic of COVID-19 has brought in light the necessity for the development of novel detection methods for airborne transmitted pathogens, and the…

Although the risk was greater with moderate-to-severe infections, even mild cases were linked to more than double the risk.

Medical News: In a deeply alarming medical case, doctors in China have issued a grave warning: COVID-19 can lead to catastrophic neurological damage in children, including irreversible brain death. The case of an 8-year-old girl who succumbed to a rapidly progressing brain injury caused by SARS-CoV-2 infection has shocked pediatric experts and added to mounting concerns over the virus’s unde...

The emergence of the SARS-CoV-2 saltation variant BA.3.2, which harbors over 50 mutations relative to its ancestral BA.3 lineage, has raised concerns about its potential to drive outbreaks similar to BA.2.86/JN.1. Concurrently, variants such as NB.1.8.1, LF.7.9, XEC.25.1, XFH, and XFG exhibit enhanced growth advantages over LP.8.1.1, necessitating a comparative analysis of their antigenic and virological characteristics. Here, we evaluated the infectivity, ACE2-binding efficiency, and immune evasion of these variants. Pseudovirus assays revealed BA.3.2’s robust antibody evasion, including resistance to Class 1/4 monoclonal antibodies; however, its ACE2 engagement efficiency was markedly reduced due to a closed spike conformation, leading to low infectivity. While XFG and LF.7.9 demonstrated strong immune escape associated with A475V and N487D mutations, their reduced receptor-binding efficiency suggested a need for compensatory adaptations. In contrast, NB.1.8.1 retained high ACE2 affinity and humoral immune evasion, supporting its potential for future dominance. Collectively, BA.3.2’s current profile limits its ability to compete with emerging variants like NB.1.8.1. Sustained monitoring of BA.3.2’s evolution— particularly for mutations stabilizing an open RBD conformation or enhancing escape from Class 1 antibodies—is essential to assess its outbreak potential.

The COVID-19 pandemic had profound effects on vocal health, impacting both infected individuals, professional voice users and essential workers. The objective of this paper was to explore the multifa...

Is a multicomponent vaccine against seasonal influenza and SARS-CoV-2 (mRNA-1083) immunogenic and well-tolerated in adults 50 years and older? Findings In this phase 3 study, mRNA-1083 elicited noninferior immune responses against standard care immunization: licensed standard-dose or high-dose seasonal influenza vaccine (A/H1N1, A/H3N2, B/Victoria, B/Yamagata) coadministered with licensed SARS-CoV-2 (Omicron XBB.1.5) vaccine. The multicomponent vaccine mRNA-1083 had an acceptable tolerability and safety profile. Meaning mRNA-1083 was demonstrated to be at least as immunogenic as recommended standard care vaccines against both seasonal influenza and COVID-19 and well-tolerated in adults 50 years and older.

Coronavirus disease 2019 (COVID-19) is characterized by multiple effects on cardiovascular and autonomic functioning. As moment-to-moment cardiovascular function is highly susceptible to mental stress, this has spurred concerns regarding the potential long-term consequences of COVID-19 on sufferers' resilience to psychological stress and stress-related cardiovascular complications. However, the long-term after-effects of COVID-19 on cardiovascular stress reactivity profiles remain relatively unexplored. To address this gap, we investigated dynamic changes in cardiovascular function during and after successive stress exposures as a function of participants' COVID-19 histories. Method Our sample comprised 60 adult members of running clubs (mean age ± SD = 44.85 ± 9.64 yrs; 50 % male; 50 % female), who were classified into one of three groups based on self-reported history of COVID-19 (never had COVID-19; had COVID-19 once; had COVID-19 multiple times). Participants underwent a laboratory-based stress-induction protocol, during which a mental arithmetic challenge was presented twice. Heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were measured before and during both stress exposures, which facilitated an assessment of habituation of cardiovascular stress responses. Results History of COVID-19 was associated with disrupted cardiovascular stress response habituation. Specifically, persons classified as having never been infected with COVID-19 exhibited lower DBP responses to the second stress exposure compared to the first, indicative of ordinary habituation as observed in previous research. Furthermore, history of COVID-19 was associated with significantly elevated average HR throughout the procedure. Conclusions Response habituation is an ordinary mechanism that protects an organism from the rigors of recurring daily stress. If COVID-19 disrupts habituation of cardiovascular system responses, then individuals who have experienced COVID-19 in the past may be left with lingering effects that increase their susceptibility to future stress-related cardiovascular ill-health. Given the substantial number of people worldwide who have been affected by COVID-19, this potential long-lasting impact merits comprehensive investigation. Cardiovascular reactivity Stress Stress responding COVID-19 Stress response habituation